4397-14-2

Basic information

• Product Name: 3,5-Dimethyl-4-hydroxybenzenemethanol
• Synonyms: 3,5-Dimethyl-4-hydroxybenzenemethanol;4-Hydroxy-3,5-dimethylbenzenemethanol;4-Hydroxy-3,5-dimethylbenzyl alcohol;2,6-dimethyl-4-methylol-phenol
• CAS NO: 4397-14-2
• Molecular Formula: C₉H₁₂O₂
• Molecular Weight: 152.19
• Mol File: 4397-14-2.mol

Chemical Properties

• Boiling Point: 293.8°C at 760 mmHg
• Flash Point: 143.5°C
• Appearance: /
• Density: 1.133g/cm³
• Vapor Pressure: 0.000766mmHg at 25°C
• Refractive Index: 1.573
• CAS DataBase Reference: 3,5-Dimethyl-4-hydroxybenzenemethanol(CAS DataBase Reference)
• NIST Chemistry Reference: 3,5-Dimethyl-4-hydroxybenzenemethanol(4397-14-2)
• EPA Substance Registry System: 3,5-Dimethyl-4-hydroxybenzenemethanol(4397-14-2)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 4397-14-2(Hazardous Substances Data)

Usage

General Description

3,5-Dimethyl-4-hydroxybenzenemethanol, also known as 3,5-xylenol, is a chemical compound with the molecular formula C9H12O2. 3,5-Dimethyl-4-hydroxybenzenemethanol belongs to the class of phenolic compounds and is commonly used as an intermediate in the production of various industrial chemicals, including antioxidants, plasticizers, and fragrances. It is a colorless to pale yellow liquid with a characteristic phenolic odor, and it is soluble in organic solvents but insoluble in water. 3,5-xylenol is also used as a preservative in personal care products and as an antimicrobial agent in industrial applications. However, it is important to handle this chemical with care, as it can be harmful if ingested, inhaled, or absorbed through the skin.

InChI:InChI=1/C9H12O2/c1-6-3-8(5-10)4-7(2)9(6)11/h3-4,10-11H,5H2,1-2H3

Upstream product

• 50-00-0 formaldehyd 
• 576-26-1 2.6-dimethylphenol 
• 527-60-6 Mesitol 
• 2233-18-3 4-hydroxy-3,5-dimethylbenzaldehyde 
• 83037-97-2 4-hydroxy-3,5-dimethylbenzyltrimethylammonium iodide 
• 36197-06-5 2,6-dimethyl-p-quinone methide 
• 48042-47-3 diethyl phosphate 
• 47017-75-4 dibenzyl phosphate 
• 32288-01-0 dibutyl phosphate anion 
• 34137-14-9 methyl 4-hydroxy-3,5-dimethylbenzoate 
• 87-62-7 2,6-dimethylaniline 
• 4919-37-3 3,5-dimethyl-4-hydroxybenzoic acid 

Downstream Products

• 2786-80-3 4-hydroxy-3,5-dimethoxyazobenzene 
• 30128-02-0 2,6-dimethyl-[1,4]benzoquinone-4-(4-hydroxy-phenylimine) 
• 527-60-6 Mesitol 
• 2233-18-3 4-hydroxy-3,5-dimethylbenzaldehyde 
• 25347-59-5 3,5,3',5'-tetramethyl-stilbene-4,4'-diol 
• 6476-26-2 4,4’-(ethane-1,2-diyl)bis(2,6-dimethylphenol) 
• 5384-21-4 bis(4-hydroxy-3,5-dimethylphenyl)methane 
• 527-61-7 2,6-dimethyl-1,4-benzoquinone 
• 4103-68-8 bis-(4-hydroxy-3,5-dimethyl-benzyl)-sulfide 
• 45952-56-5 3,5-dimethyl-4-hydroxybenzyl bromide 
• 71655-87-3 4,4'-(oxybis(methylene))bis(2,6-dimethylphenol) 
• 50-00-0 formaldehyd 
• 43109-10-0 2,6-dimethyl-4-[(E)-(2,4-dinitrophenyl)diazenyl]phenol 
• 85628-42-8 2,6-Dimethyl-4-(2-methyl-2-nitropropyl)phenol 

Relevant articles and documents

LIPID PRODRUGS OF NEUROSTEROIDS

The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.

Unusual transformation of 4-hydroxy/methoxybenzylic alcohols via C[sbnd]C ipso-substitution reaction using proton-exchanged montmorillonite as media

We present here proton-exchanged montmorillonite-mediated an unusual transformation of 4-hydroxy and 4-methoxybenzylic alcohols to form symmetrical benzylic ethers and diarylmethanes under mild conditions. Nuclear magnetic resonance spectroscopy and density functional theory calculations support a plausible mechanism, which includes a distinctive aromatic C[sbnd]C ipso-substitution reaction with a hydroxymethyl group as the C-based leaving group.

LIPID PRODRUGS OF PREGNANE NEUROSTEROIDS AND USES THEREOF

The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.

LIPID PRODRUGS OF JAK INHIBITORS AND USES THEREOF

The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, and methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.

LIPID PRODRUGS OF BTK INHIBITORS AND USES THEREOF

The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, and methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.

LIPID PRODRUGS OF GLUCOCORTICOIDS AND USES THEREOF

The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, and methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.

Phenolic Oxidation Using H2O2 via in Situ Generated para-Quinone Methides for the Preparation of para-Spiroepoxydienones

Phenols are attractive starting materials for the preparation of highly substituted cyclohexane rings via dearomative processes. Herein we report an efficient preparation of dearomatized 1-oxaspiro[2.5]octa-4,7-dien-6-ones (para-spiroepoxydienones) via the nucleophilic epoxidation of in situ generated para-quinone methides from 4-(hydroxymethyl)phenols using aqueous H2O2. The developed protocol bypasses the need for stoichiometric bismuth reagents or diazomethane, which are frequently deployed for p-spiroepoxydienone preparation. The p-spiroepoxydienones are further elaborated in numerous downstream complexity-building transformations.

Optimization of sulfonamide derivatives as highly selective EP1 receptor antagonists

A series of 4-[(2-{isobutyl[(5-methyl-2-furyl)sulfonyl]amino}phenoxy)methyl]benzoic acids and 4-({2-[isobutyl(1,3-thiazol-2-ylsulfonyl)amino]phenoxy}methyl)benzoic acids were synthesized and evaluated for their EP receptor affinities and EP1 receptor anta

Unexpected 2,4,6-trimethylphenol oxidation in the presence of Fe(III) aquacomplexes

2,4,6-Trimethylphenol (TMP) was efficiently oxidised by Fe(III) aquacomplexes. HPLC analysis was used to follow the kinetics of the redox process. Two degradation products were detected and identified: 2,6-dimethyl-4-(hydroxymethyl)phenol (P1) and 3,5-dimethyl-4-hydroxybenzaldehyde (P2) accounting for 100% of TMP degradation in the early stages of the reaction. The formation of the products was concomitant with the reduction of Fe(III) into Fe(II). The direct relation between TMP oxidation and the concentration of the monomeric species {Fe(H2O)5(OH)} 2+ gives evidence for the initial reaction to take place between TMP and this particular species. Moreover, the correlation between P2 formation and P1 disappearance during the reaction implies the sequence of reactions: TMP → P1 → P2. A mechanism leading to the two degradation products is proposed. the Royal Society of Chemistry and the Centre National de la Recherche Scientifique 2006.

NOVEL ACYLATING REAGENTS

Novel acylating agents useful for preparing activated nucleophiles such as terminally activated polymers are disclosed. In preferred aspects, the acylating agents are formula (I) and formula (II) and they used to prepare activated polymers such as PEG's f